文献速递乳腺癌

三阴性乳腺癌中从头嘧啶合成的适应性重编程是一种代谢脆弱性

Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.
PubMed 文献 · Cancer Discov · 2017-03-02

该研究通过体外和体内代谢谱分析发现,三阴性乳腺癌(TNBC)细胞在化疗暴露后嘧啶核苷酸丰度增加,且依赖从头嘧啶合成通路活性升高。药理学抑制该通路可加剧DNA损伤,使TNBC细胞对基因毒性化疗敏感;多柔比星与来氟米特联合治疗诱导TNBC异种移植瘤消退。

要点

  • 化疗暴露后TNBC细胞嘧啶核苷酸丰度增加,依赖从头嘧啶合成通路活性升高。
  • 药理学抑制从头嘧啶合成可加剧DNA损伤,使TNBC细胞对基因毒性化疗敏感。
  • 多柔比星与来氟米特联合治疗诱导TNBC异种移植瘤消退。

核心结论

  • 化疗暴露后嘧啶核苷酸水平升高代表一种代谢脆弱性,可利用临床已批准的从头嘧啶合成抑制剂增强TNBC化疗疗效。

研究设计与样本

  • 研究采用TNBC细胞的体外和体内代谢谱分析。
  • 联合治疗实验使用多柔比星与来氟米特(临床已批准的从头嘧啶合成通路抑制剂)处理TNBC异种移植瘤。

主要发现

  • TNBC细胞化疗暴露后嘧啶核苷酸丰度增加。
  • 化疗诱导的嘧啶核苷酸升高依赖于从头嘧啶合成通路活性增加。
  • 药理学抑制从头嘧啶合成通过加剧DNA损伤使TNBC细胞对基因毒性化疗药物敏感。
  • 多柔比星与来氟米特联合治疗诱导TNBC异种移植瘤消退。

临床怎么用

  • 作者认为,化疗暴露后嘧啶核苷酸水平升高是可利用的代谢脆弱性,可增强TNBC化疗疗效。
  • 作者指出,可使用临床已批准的从头嘧啶合成抑制剂使TNBC细胞对化疗敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy resistance is a major barrier to the treatment of triple-negative breast cancer (TNBC), and strategies to circumvent resistance are required. Using in vitro and in vivo metabolic profiling of TNBC cells, we show that an increase in the abundance of pyrimidine nucleotides occurs in response to chemotherapy exposure. Mechanistically, elevation of pyrimidine nucleotides induced by chemotherapy is dependent on increased activity of the de novo pyrimidine synthesis pathway. Pharmacologic inhibition of de novo pyrimidine synthesis sensitizes TNBC cells to genotoxic chemotherapy agents by exacerbating DNA damage. Moreover, combined treatment with doxorubicin and leflunomide, a clinically approved inhibitor of the de novo pyrimidine synthesis pathway, induces regression of TNBC xenografts. Thus, the increase in pyrimidine nucleotide levels observed following chemotherapy exposure represents a metabolic vulnerability that can be exploited to enhance the efficacy of chemotherapy for the treatment of TNBC.Significance: The prognosis for patients with TNBC with residual disease after chemotherapy is poor. We find that chemotherapy agents induce adaptive reprogramming of de novo pyrimidine synthesis and show that this response can be exploited pharmacologically, using clinically approved inhibitors of de novo pyrimidine synthesis, to sensitize TNBC cells to chemotherapy. Cancer Discov; 7(4); 391-9. ©2017 AACR.See related article by Mathur et al., p. 380This article is highlighted in the In This Issue feature, p. 339.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Brown KK, Spinelli JB, Asara JM, et al. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2017. PMID: 28255083. doi:10.1158/2159-8290.CD-16-0611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。